long intergenic non-protein coding RNA 2525Genealiases: TP53LC14 · lncNB1
Q-omics provides the consensus-scored LINC02525 profile across patient tissues and cancer cell-line models. LINC02525 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LINC02525 is differentially expressed in 9, with the highest sampling consensus in UCEC. Additionally, LINC02525 RNA expression shows 8,805 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, UCEC, and TGCT as cancer lineages where LINC02525 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02525 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02525 survival associations across molecular data types. LINC02525 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02525 RNA expression–survival associations across cancer types. High LINC02525 expression shows unfavorable associations in LGG and LIHC, but favorable associations in OV, KICH, LUAD and UVM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LINC02525 RNA expression.
This table summarizes LINC02525 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02525. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02525 shows lower tumor expression in UCEC and KIRP and higher tumor expression in COAD, CHOL, LIHC and LUSC. The UCEC box plot shows higher LINC02525 RNA expression in normal versus tumor tissue (log2 FC = −0.456, t-test p < 0.001).
This table shows molecular features associated with LINC02525 in patient tissues and cancer cell lines. In patient samples, LINC02525 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
